Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives
- Author(s)
- Prince, HM; Hutchings, M; Domingo-Domenech, E; Eichenauer, DA; Advani, R;
- Journal Title
- Annals of Hematology
- Publication Type
- Review
- Abstract
- CD30 is overexpressed in several lymphoma types, including classic Hodgkin lymphoma (cHL), some peripheral T-cell lymphomas (PTCL), and some cutaneous T-cell lymphomas. The antibody-drug conjugate brentuximab vedotin targets CD30-positive cells and has been evaluated for the treatment of various lymphoma entities. This narrative review summarizes 10 years of experience with brentuximab vedotin for the treatment of CD30-positive lymphomas, discusses novel therapies targeting CD30 in development, and highlights remaining controversies relating to CD30-targeted therapy across lymphoma types. The collective body of evidence for brentuximab vedotin demonstrates that exploitation of CD30 can provide sustained benefits across a range of different CD30-positive lymphomas, in both clinical trials and real-world settings. Preliminary experience with brentuximab vedotin in combination with immune checkpoint inhibitors for relapsed/refractory cHL is encouraging, but further exploration is required. The optimal use of brentuximab vedotin for first-line therapy of PTCL remains to be determined. Further research is required on brentuximab vedotin treatment in high-risk patient populations, and in rare lymphoma subtypes, for which no standard of care exists. Novel therapies targeting CD30 include chimeric antigen receptor therapies and bispecific antibody T-cell engagers, which may be expected to further improve outcomes for patients with CD30-positive lymphomas in the coming years.
- Publisher
- Springer Nature
- Keywords
- Humans; Brentuximab Vedotin/therapeutic use; Ki-1 Antigen; *Immunoconjugates; *Antineoplastic Agents/therapeutic use; *Hodgkin Disease/pathology; *Lymphoma, T-Cell, Cutaneous; *Lymphoma, T-Cell, Peripheral/drug therapy; *Skin Neoplasms/drug therapy
- Department(s)
- Clinical Haematology
- PubMed ID
- 36512081
- Publisher's Version
- https://doi.org/10.1007/s00277-022-05054-9
- Open Access at Publisher's Site
https://doi.org/10.1007/s00277-022-05054-9- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-06-13 07:55:18
Last Modified: 2023-06-13 07:56:08